IceCure Medical Expands Patent Portfolio with New US Approval
Company Announcements

IceCure Medical Expands Patent Portfolio with New US Approval

Icecure Medical (ICCM) has released an update.

IceCure Medical has received a Notice of Allowance from the U.S. Patent and Trademark Office for its innovative Cryogenic System Connector, a crucial part of its next-generation cryoablation system. This development bolsters IceCure’s position as a leader in the cryoablation market, which is valued at $1.67 billion globally, by enhancing their intellectual property portfolio and potential market reach. With over 50 patents and FDA clearance for its XSense cryoprobes, IceCure is poised to meet significant unmet needs in tumor ablation.

For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskIceCure Medical’s ProSense® Gains FDA Panel Support
TheFlyIceCure Medical announces FDA’s favorable recommendation for ProSense
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App